Date: 26 February 2026
Closing Price: 2280
Day’s Gain: +5.75%
RSI: 68
Mankind Pharma witnessed a strong bullish session backed by high volumes, signaling renewed buying interest after a sharp correction from its 52-week high. Importantly, the stock has now achieved its 1/3 recovery level, strengthening the case for a short-term trend reversal.
Technical Analysis
Recent Price Structure
30-Day Low: 2015 (23 Feb 2026)
30-Day High: 2285 (26 Feb 2026)
52-Week High: 2727 (15 July 2025)
52-Week Low: 2015 (23 Feb 2026)
The stock has corrected by 712 points from its 52 week high to yearly low. The recent bounce from 2015 marks a potential base formation zone, as the stock defended its 52-week low and responded with strong upward momentum.
Moving Averages & Momentum
Mankind Pharma reclaimed its 30 DMA of 2098 on 25 Feb 2026 which is an early bullish signal. Sustained move above 50 DMA of 2136 has strengthened short-term trend. A decisive breakout above 200 DMA (2362) would confirm a medium-term trend reversal. RSI at 68 indicates strong bullish momentum. If the RSI sustains between 60–75 with price consolidating above 2250 and volume expansion on breakout toward 2371, it would confirm institutional accumulation.
Recovery Levels
After a correction of 712 points, the 1/3, 1/2 and 2/3 recovery levels are 2252, 2371, 2490 respectively. The stock has successfully crossed the 1/3 recovery level, which often acts as the first technical confirmation that selling pressure is reducing. Sustaining above this level improves probability of testing 2371.
The immediate resistance is at 1/2 recovery point while major resistance is at 2362–2400 zone (200 DMA confluence). Immediate support is at 50 DMA (2136) while structural support at 52 week low of 2015. Mankind Pharma appears to be in the early stages of recovery after a deep correction. Achieving the 1/3 recovery level signals improving sentiment. However, confirmation of a sustained bullish trend would require holding above 2250 and eventually reclaiming the 200 DMA zone.
Q3 FY26 Results Overview
For the quarter ended December 2025:
Revenue: 3567 crore (+11.5% YoY)
Net Profit: 414 crore (+9.5% YoY)
EBITDA Margin: ~22.9%
Growth was supported by improved performance in cardiac and anti-diabetic segments, along with consolidation benefits from the Bharat Serums integration.
About Mankind Pharma
Mankind Pharma is one of India’s leading pharmaceutical companies with strong presence in Acute & Chronic therapies, Consumer healthcare (OTC brands), and Women’s health & specialty segments. The company continues to strengthen its chronic portfolio while maintaining leadership in mass-market formulations.
0 Comments